{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:33:17Z","timestamp":1772800397987,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T00:00:00Z","timestamp":1634342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T00:00:00Z","timestamp":1634342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s40261-021-01088-5","type":"journal-article","created":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T19:06:34Z","timestamp":1634411194000},"page":"999-1010","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["First-in-Human, Single-Ascending Dose and Food Effect Studies to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cetagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus"],"prefix":"10.1007","volume":"41","author":[{"given":"Lu","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinmiao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sufeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sijia","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daosheng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juping","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangtao","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,16]]},"reference":[{"key":"1088_CR1","unstructured":"International Diabetes Federation. IDF diabetes atlas. 9th ed. 2019. https:\/\/diabetesatlas.org\/en\/. Accessed 7 Oct 2019."},{"issue":"34","key":"1088_CR2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011946","volume":"97","author":"X Wang","year":"2018","unstructured":"Wang X, Li X, Qie S, Zheng Y, Liu Y, Liu G. The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus: a systemic review and meta-analysis. Medicine (Baltimore). 2018;97(34): e11946. https:\/\/doi.org\/10.1097\/MD.0000000000011946.","journal-title":"Medicine (Baltimore)"},{"issue":"9548","key":"1088_CR3","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696\u2013705. https:\/\/doi.org\/10.1016\/S0140-6736(06)69705-5.","journal-title":"Lancet"},{"issue":"7","key":"1088_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2165\/00003088-200847070-00001","volume":"47","author":"CB Landersdorfer","year":"2008","unstructured":"Landersdorfer CB, Jusko WJ. Pharmacokinetic\/pharmacodynamic modelling in diabetes mellitus. Clin Pharmacokinet. 2008;47(7):417\u201348. https:\/\/doi.org\/10.2165\/00003088-200847070-00001.","journal-title":"Clin Pharmacokinet"},{"key":"1088_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.06.004","volume":"136","author":"ZP Gou","year":"2019","unstructured":"Gou ZP, Wang ZL, Liang XF, Zheng L, Wang Y, Feng P. Single-dose escalation study of yogliptin in healthy Chinese volunteers. Eur J Pharm Sci. 2019;136: 104950. https:\/\/doi.org\/10.1016\/j.ejps.2019.06.004.","journal-title":"Eur J Pharm Sci"},{"issue":"Suppl. 1","key":"1088_CR6","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1517\/14740338.2014.944862","volume":"13","author":"A Ceriello","year":"2014","unstructured":"Ceriello A, Sportello L, Rafaniello C, Rossi F. DPP-4 inhibitors: pharmacological differences and their clinical implications. Expert Opin Drug Saf. 2014;13(Suppl. 1):S57-68. https:\/\/doi.org\/10.1517\/14740338.2014.944862.","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"1088_CR7","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1210\/en.2010-0115","volume":"151","author":"PL Bubaker","year":"2010","unstructured":"Bubaker PL. Minireview: update on incretin biology: focus on glucagon-like peptide-1. Endocrinology. 2010;151(5):1984\u20139. https:\/\/doi.org\/10.1210\/en.2010-0115.","journal-title":"Endocrinology"},{"issue":"1\u20132","key":"1088_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.mce.2008.08.012","volume":"297","author":"JJ Holst","year":"2009","unstructured":"Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol. 2009;297(1\u20132):127\u201336. https:\/\/doi.org\/10.1016\/j.mce.2008.08.012.","journal-title":"Mol Cell Endocrinol"},{"issue":"12","key":"1088_CR9","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/j.1463-1326.2008.00887.x","volume":"10","author":"L Xu","year":"2008","unstructured":"Xu L, Man CD, Charbonnel B, Meninger G, Davies MJ, Williams-Herman D, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab. 2008;10(12):1212\u201320. https:\/\/doi.org\/10.1111\/j.1463-1326.2008.00887.x.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"1088_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/BF03261927","volume":"51","author":"LK Golightly","year":"2012","unstructured":"Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012;51(8):501\u201314. https:\/\/doi.org\/10.1007\/BF03261927.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1088_CR11","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.clpt.2005.09.002","volume":"78","author":"GA Herman","year":"2005","unstructured":"Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, Smet MD, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005;78(6):675\u201388. https:\/\/doi.org\/10.1016\/j.clpt.2005.09.002.","journal-title":"Clin Pharmacol Ther"},{"key":"1088_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00498254.2021.1963010","volume":"11","author":"J Lu","year":"2021","unstructured":"Lu J, Tian X, Tang D, Zhou X, Xu Z, Ding J, Wang T, et al. In vitro study of the drug-drug interaction potential of cetagliptin and clinical study of pharmacokinetic interaction of cetagliptin and metformin in healthy volunteers. Xenobiotica. 2021;11:1\u201310. https:\/\/doi.org\/10.1080\/00498254.2021.1963010.","journal-title":"Xenobiotica"},{"key":"1088_CR13","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1177\/009286159502900324","volume":"29","author":"K Gough","year":"1995","unstructured":"Gough K, Hutchison M, Keene O, Byrom B, Ellis S, Lacey L, et al. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry\/pharmacokinetics UK joint working party. Drug Info J. 1995;29:1039\u201348.","journal-title":"Drug Info J."},{"issue":"10","key":"1088_CR14","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1023\/a:1026451721686","volume":"17","author":"BP Smith","year":"2000","unstructured":"Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000;17(10):1278\u201383. https:\/\/doi.org\/10.1023\/a:1026451721686.","journal-title":"Pharm Res"},{"issue":"3","key":"1088_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.4994","volume":"35","author":"H Bai","year":"2021","unstructured":"Bai H, Lu J, Cheng X, Liu L, Zhang W, Wei Y, et al. Development and validation of an ultrasensitive LC-MS\/MS method for the quantification of cetagliptin in human plasma and its application in a microdose clinical trial. Biomed Chromatogr. 2021;35(3): e4994. https:\/\/doi.org\/10.1002\/bmc.4994.","journal-title":"Biomed Chromatogr"},{"issue":"1","key":"1088_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40262-016-0421-4","volume":"56","author":"DW Boulton","year":"2017","unstructured":"Boulton DW. Clinical pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor. Clin Pharmacokinet. 2017;56(1):11\u201324. https:\/\/doi.org\/10.1007\/s40262-016-0421-4.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1088_CR17","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.clinthera.2008.03.005","volume":"30","author":"R Christopher","year":"2008","unstructured":"Christopher R, Covington P, Davenport M, Fleck P, Mekki QA, Wann ER, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther. 2008;30(3):513\u201327. https:\/\/doi.org\/10.1016\/j.clinthera.2008.03.005.","journal-title":"Clin Ther"},{"issue":"9","key":"1088_CR18","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1177\/0091270007304313","volume":"47","author":"G Sunkara","year":"2007","unstructured":"Sunkara G, Sabo R, Wang Y, He Y, Campestrini J, Rosenberg M, et al. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. J Clin Pharmacol. 2007;47(9):1152\u20138. https:\/\/doi.org\/10.1177\/0091270007304313.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1088_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1211\/jpp\/61.01.0008","volume":"61","author":"H Fuchs","year":"2009","unstructured":"Fuchs H, Tiliement JP, Urien S, Greischel A, Roth W. Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. J Pharm Pharmacol. 2009;61(1):55\u201362. https:\/\/doi.org\/10.1211\/jpp\/61.01.0008.","journal-title":"J Pharm Pharmacol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01088-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-021-01088-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01088-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T04:33:08Z","timestamp":1635568388000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-021-01088-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,16]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1088"],"URL":"https:\/\/doi.org\/10.1007\/s40261-021-01088-5","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,16]]},"assertion":[{"value":"28 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by CGeneTech (Suzhou, China) Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jinmiao Lu, Juping Ding and Qiang Yu are employees of CGeneTech (Suzhou, China) Co., Ltd, which is the funder of this study. Daosheng Xie is an employee of Beijing Noahpharm Medical Technology Co., Ltd., the contract research organization that performed this study.\u00a0Other authors have no conflict in interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study protocols were conducted in accordance with the guidelines on good clinical practice and with ethical standards for human experimentation established by the Declaration of Helsinki. The studies were registered at  (Nos. CTR20180167 and CTR20181331). The protocols were approved by the Ethics Committee of the First Affiliated Hospital with Nanjing Medical University (Nanjing, China).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data are not available in a repository, but reasonable requests can be directed to Feng Shao at jsphshaofeng@hotmail.com.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"LW, FS, JL, DX, JD and QY contributed to the conception and design of the study. Material preparation and data collection were performed by SZ, LX, CZ, JC and SD. Analysis was performed by YZ, HS and GH. Data analysis and writing were performed by LW. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}